Bidirectional Mendelian randomization and potential mechanistic insights into the causal relationship between gut microbiota and malignant mesothelioma

June 6, 2025 | Comments Off on Bidirectional Mendelian randomization and potential mechanistic insights into the causal relationship between gut microbiota and malignant mesothelioma

Medicine 2025 April 25 [Link] Yinjie Zhou, Huangkai Zhu, Long Zhao, Guofang Zhao, Jiaen Sun Abstract Malignant mesothelioma (MM) is a rare but aggressive cancer originating from mesothelial cells, which…

The Mesothelioma Systemic Inflammation Score Is Independently Associated with Overall Survival and Predicts Benefit of Multimodality Treatment in Pleural Mesothelioma

June 5, 2025 | Comments Off on The Mesothelioma Systemic Inflammation Score Is Independently Associated with Overall Survival and Predicts Benefit of Multimodality Treatment in Pleural Mesothelioma

Cancers 2025 April 20 [Link] Berta Mosleh, Katharina Sinn, Anna Cho, Anton Reiner, Ariane Steindl, Christian Lang, Sabine Zöchbauer-Müller, Karin Dieckmann, Joachim Widder, Helmut Prosch, Balazs Dome, Karin Schelch, Clemens…

Efficacy of Immunotherapy Versus Chemotherapy in Advanced Pleural Mesothelioma: A Turkish Oncology Group (TOG) Study

June 4, 2025 | Comments Off on Efficacy of Immunotherapy Versus Chemotherapy in Advanced Pleural Mesothelioma: A Turkish Oncology Group (TOG) Study

Medicina 2025 March 31 [Link] Ziya Kalkan, Senar Ebinc, Murat Arcagok, Ahmet Bilici, Ozcan Yildiz, Saadettin Kilickap, Deniz Can Guven, Ali Murat Tatli, Ahmet Taner Sumbul, Nil Molinas Mandel, Akin…

Tumor Treating Fields (TTFields) Therapy in Unresectable Pleural Mesothelioma: Overview of Efficacy, Safety, and Future Outlook

June 3, 2025 | Comments Off on Tumor Treating Fields (TTFields) Therapy in Unresectable Pleural Mesothelioma: Overview of Efficacy, Safety, and Future Outlook

Current Treatment Options in Oncology 2025 May [Link] Giovanni Luca Ceresoli, Letizia Gianoncelli Abstract Pleural mesothelioma is an incurable cancer with unmet diagnostic and therapeutic needs. Due to its pattern…

Immunotherapy in mesothelioma – systematic review and meta-analysis of immunotherapy impact on OS and its correlation with PFS and ORR

June 2, 2025 | Comments Off on Immunotherapy in mesothelioma – systematic review and meta-analysis of immunotherapy impact on OS and its correlation with PFS and ORR

Journal of Chemotherapy 2025 April 22 [Link] Marko Skelin, Kaja Matić, Andrea Anić-Matić, Ivan Krečak, Bruna Perkov-Stipičin, Mirko Grubor Abstract Mesothelioma has a poor prognosis, with a 5-year overall survival…

Efficacy and safety of bintrafusp alfa evaluated in a phase II single-arm clinical trial in previously treated advanced pleural mesothelioma

May 30, 2025 | Comments Off on Efficacy and safety of bintrafusp alfa evaluated in a phase II single-arm clinical trial in previously treated advanced pleural mesothelioma

Lung Cancer 2025 May [Link] Ernest Nadal, Paloma Martín-Martorell, Jose Carlos Benítez, Maria Ángeles Sala, Susana Cedrés, Carlos Álvarez, Manuel Dómine, Elia Sais 8, Maria Saigí, Rafael López, Laia Vilà,…

Cytoplasmic HuR Expression Enhances Chemoresistance in Pleural Mesothelioma Through Increased Expression of CALB2, Promotion of the E2F Pathway, and Suppression of the p53 Pathway

May 29, 2025 | Comments Off on Cytoplasmic HuR Expression Enhances Chemoresistance in Pleural Mesothelioma Through Increased Expression of CALB2, Promotion of the E2F Pathway, and Suppression of the p53 Pathway

Thoracic Cancer 2025 April [Link] Susumu Kirimura, Morito Kurata, Hironori Ishibashi, Yusuke Taniguchi, Yuko Kinowaki, Keisuke Sugita, Kenichi Okubo Abstract Introduction: Chemotherapy is crucial for treating pleural mesothelioma; however, the…

Radical hemithorax radiotherapy induces an increase in circulating PD-1+ T lymphocytes and in the soluble levels of PD-L1 in malignant pleural mesothelioma patients: a possible synergy with PD-1/PD-L1 targeting treatment?

May 28, 2025 | Comments Off on Radical hemithorax radiotherapy induces an increase in circulating PD-1+ T lymphocytes and in the soluble levels of PD-L1 in malignant pleural mesothelioma patients: a possible synergy with PD-1/PD-L1 targeting treatment?

Frontiers in Immunology 2025 April 1 [Link] Alberto Revelant, Francesca Gessoni, Marcella Montico, Raja Dhibi, Giulia Brisotto, Mariateresa Casarotto, Martina Zanchetta, Veronica Paduano, Filippo Sperti, Chiara Evangelista, Fabiana Giordari, Valli…

Incidence and Outcomes of Brain Metastasis in Pleural Mesothelioma in the Era of Immunotherapy

May 27, 2025 | Comments Off on Incidence and Outcomes of Brain Metastasis in Pleural Mesothelioma in the Era of Immunotherapy

JTO Clinical & Research Reports 2025 March 10 [Link] Margaret Stalker, Suzanne L Walker, Emily Lebow, Emily Ling-Lin Pai, Alex Watts, Wei-Ting Hwang, Amir Banihashemi, Evan Anderson, Leonid Roshkovan, Sharyn…

Multicystic peritoneal mesothelioma with floret-like multinucleated giant cells: A case report

May 27, 2025 | Comments Off on Multicystic peritoneal mesothelioma with floret-like multinucleated giant cells: A case report

Revista Espanola de Patologica 2025 April 10 [Link] Robert Ricardo Rodríguez Carpio, Carlos Hörndler Argarate, Sandra Vicente Arregui, María Francisca Perulero Martín, Leticia Ollero Domenche Abstract Multicystic peritoneal mesothelioma is…

Categories